accredited investor lead

BTV Explores Investment Options in Life Sciences

On national TV Sat. May 8 & Sun. May 9, 2021 - BTV-Business Television explores life science investment opportunities including psychedelic-based therapies and home COVID-19 tests.

Discover Companies to Invest In - Click company name to watch their TV feature:

Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) - BTV learns how this company is revolutionizing healthcare by using psychedelic molecules to address mental health disorders.

Lexaria Bioscience Corp. (CSE: LXX) (NASDAQ: LEXX) - A leading bioscience company whose patented technology, DehyraTECH, provides a faster and more effective drug delivery method.

StageZero Life Sciences Ltd. (TSX: SZLS) - BTV learns about this company's next generation test that can detect up to ten different cancers in one sample of blood.

NeonMind Biosciences(CSE: NEON) (OTC: NMDBF) - Obesity is one of the world's biggest health issues. BTV weighs in on this novel psychedelic treatment approach to tackle the issue.

Empower Clinics Inc. (CSE: CBDT) - Is providing body and mind wellness for over 200,000 patients through its US and Canadian clinics, a telemedicine platform, home COVID-19 test kits and a world-class medical diagnostics laboratory in Texas.


On air for over 20 years, BTV - Business Television, a half-hour investment TV show, features analysts and emerging companies on location. With Hosts, Taylor Thoen and Jessica Katrichak, BTV brings viewers investment opportunities.

TV BROADCAST NETWORKS and TIMES:
CANADA:

BNN Bloomberg - Saturday May 8 @ 8:00pm EST, Sunday May 9 @ 4:30pm EST
Bell Express Vu - Saturday May 8 @ 8:00pm EST, Sunday May 9 @ 4:30pm EST

US National TV:
Biz Television Network - Sun May 16 @ 8:30am EST

Suggest a Company to Feature!
Contact: (604) 664-7401 x3 info@b-tv.com
To receive news, click here to subscribe.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/83068

News Provided by Newsfile via QuoteMedia

The Conversation (0)

AMGEN LAUNCHES PARTNERS OF CHOICE NETWORK OF EIGHT LEADING ONCOLOGY ACADEMIC CENTERS

Network Aims to Advance Collaboration Across Industry and Academia to Accelerate Treatment Development for Patients

Inaugural Scientific Summit Prioritized Advancing Translational Research, Pharmacodynamic Readouts and Innovative Biomarker-Driven Programs

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less
Cardiol Therapeutics Announces All Collaborating Clinical Research Centers Now Initiated and Eligible to Enroll Patients in ARCHER, a Phase II Trial of CardiolRx for the Treatment of Acute Myocarditis

Cardiol Therapeutics Announces All Collaborating Clinical Research Centers Now Initiated and Eligible to Enroll Patients in ARCHER, a Phase II Trial of CardiolRx for the Treatment of Acute Myocarditis

Recruitment Accelerating and Full Patient Enrollment Anticipated to be Completed During Q3 2024, up to Six Months Ahead of Schedule

Multi-Center, International, Double-blind, Placebo-controlled Trial Randomizing 100 Patients

News Provided by Newsfile via QuoteMedia

Keep reading...Show less

AMGEN TO PRESENT AT THE BANK OF AMERICA MERRILL LYNCH GLOBAL HEALTHCARE CONFERENCE

Amgen (NASDAQ:AMGN) will present at the Bank of America Merrill Lynch Global Healthcare Conference at 11:40 a.m. BST on Thursday Sept. 14, 2023. Peter H. Griffith executive vice president and chief financial officer at Amgen will present at the conference. The webcast will be broadcast over the internet simultaneously and will be available to members of the news media, investors and the general public.

The webcast, as with other selected presentations regarding developments in Amgen's business given by management at certain investor and medical conferences, can be found on Amgen's website, www.amgen.com , under Investors. Information regarding presentation times, webcast availability and webcast links are noted on Amgen's Investor Relations Events Calendar. The webcast will be archived and available for replay for at least 90 days after the event.

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less

AMGEN PRESENTS NEW LUMAKRAS® PLUS CHEMOTHERAPY DATA IN FIRST-LINE KRAS G12C NSCLC AT WCLC

In Phase 1b Study, Patients Treated in First-Line Demonstrated a Confirmed Objective Response Rate of 65%

Amgen (NASDAQ:AMGN) today announced exciting data from a study arm of the CodeBreaK 101 clinical trial, a Phase 1b study evaluating LUMAKRAS ® (sotorasib) with carboplatin and pemetrexed in adult patients with KRAS G12C-mutated advanced non-small cell lung cancer (NSCLC). These results were featured in an oral presentation at the International Association for the Study of Lung Cancer (IASLC) 2023 World Conference on Lung Cancer (WCLC) in Singapore on Sunday, September 10 .

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less
BriaCell Reports Benchmark-Beating Patient Survival and Clinical Benefit in Advanced Metastatic Breast Cancer

BriaCell Reports Benchmark-Beating Patient Survival and Clinical Benefit in Advanced Metastatic Breast Cancer

  • Median overall survival of 13.5 months in BriaCell's advanced metastatic breast cancer patients (vs. 6.7-9.8 months for similar patients reported in the literature)
  • 21 out of 29 patients treated since 2022 are still alive suggesting a strong survival benefit for BriaCell's combination regimen
  • No dose limiting toxicities to date

briacell therapeutics corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, today announces the completion of patient enrollment in its Phase 2 clinical study and reports clinical data showing strong patient survival benefit and clinical benefit in advanced metastatic breast cancer patients.

"The promising survival data of BriaCell's combination regimen suggests the potential for an industry-shaping leap in advanced metastatic breast cancer treatment," stated Carmen Calfa, M.D., of the Sylvester Comprehensive Cancer Center at the University of Miami, Associate Professor of Clinical Medicine, and Principal Clinical Investigator of the Phase 2 Bria-IMT™ plus check point inhibitors study. "The overall safety profile and survival data in advanced metastatic breast cancer is extremely encouraging in this heavily pre-treated patient population."

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

AMGEN TO PRESENT AT THE MORGAN STANLEY GLOBAL HEALTHCARE CONFERENCE

Amgen (NASDAQ:AMGN) will present at the Morgan Stanley Global Healthcare Conference at 8:50 a.m. ET on Tuesday, Sept. 12, 2023 . Robert A. Bradway chairman and chief executive officer at Amgen will present at the conference. The webcast will be broadcast over the internet simultaneously and will be available to members of the news media, investors and the general public.

The webcast, as with other selected presentations regarding developments in Amgen's business given by management at certain investor and medical conferences, can be found on Amgen's website, www.amgen.com , under Investors. Information regarding presentation times, webcast availability and webcast links are noted on Amgen's Investor Relations Events Calendar. The webcast will be archived and available for replay for at least 90 days after the event.

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×